Proteus Digital Health, Inc., a Redwood City, Calif.-based digital medicines company, completed a second closing of its Series G financing, raising over $172m.
On June 2, the company announced the first part of this funding series with $120m from new major institutional investors based in the United States, Europe and Asia (read here).
Proteus will use the funds to advance the manufacturing and commercialization of digital medicines.
Led by Andrew Thompson, President and Chief Executive Officer, the company is creating digital medicines, which are new pharmaceuticals that integrate medicines with ingestible, wearable, mobile and cloud computing and deliver solutions that enable patients, their families and physicians to make better decisions about health.
Proteus has received a CE mark in Europe and FDA market clearance in the U.S. for its wearable and Ingestible Sensor™ devices.
FinSMEs
29/07/2014